Absorption and tolerability of fentanyl buccal soluble film (FBSF) in patients with cancer in the presence of oral mucositis

Journal of Pain Research

Volumn 4, Issue , 2011, Pages 245-251

  Finn, Andrew L ^a   Charlie Hill, W D ^b   Tagarro, Ignacio ^c   Gever, Larry N ^d  

^a BioDelivery Sciences International Inc   (United States)

^b LumiNostix   (United States)

^c Marketing Centre CIP CNS   (Spain)

^d Meda Pharmaceuticals Inc   (United States)

Author keywords

Application site pain; Breakthrough cancer pain; Clinical study

Indexed keywords

EID: 84856176066     PISSN: 11787090     EISSN: None     Source Type: Journal    
DOI: 10.2147/JPR.S22641     Document Type: Article

References (28)

1. Elting LS, Keefe DM, Sonis ST, et al. Patient-reported measurements of oral mucositis in head and neck cancer patients treated with radiotherapy with or without chemotherapy: demonstration of increased frequency, severity, resistance to palliation, and impact on quality of life. Cancer. 2008;113(10):2704-2713.
2. Murphy BA, Beaumont JL, Isitt J, et al. Mucositis-related morbidity and resource utilization in head and neck cancer patients receiving radiation therapy with or without chemotherapy. J Pain Symptom Manage. 2009; 38(4):522-532.
3. Sonis ST. Mucositis as a biological process: a new hypothesis for the development of chemotherapy-induced stomatotoxicity. Oral Oncol. 1998;34(1):39-43.
4. Treister N, Sonis S. Mucositis: biology and management. Curr Opin Otolaryngol Head Neck Surg. 2007;15(2):123-129.
5. Trotti A, Bellm LA, Epstein JB, et al. Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review. Radiother Oncol. 2003;66(3):253-262.
6. Vera-Llonch M, Oster G, Hagiwara M, Sonis S. Oral mucositis in patients undergoing radiation treatment for head and neck carcinoma. Cancer. 2006;106(2):329-336.
7. Berger AM, Eilers J. Factors influencing oral cavity status during highdose antineoplastic therapy: a secondary data analysis. Oncol Nurs Forum. 1998;25(9):1623-1626.
8. Borbasi S, Cameron K, Quested B, Olver I, To B, Evans D. More than a sore mouth: patients' experience of oral mucositis. Oncol Nurs Forum. 2002;29(7):1051-1057.
9. Portenoy RK, Payne D, Jacobsen P. Breakthrough pain: characteristics and impact in patients with cancer pain. Pain. 1999;81(1-2):129-134.
10. Actiq (fentanyl citrate) oral transmucosal lozenge. Prescribing information. Cephalon Corp. Revised 2007.
11. Fentora (fentanyl buccal tablet). Prescribing information. Cephalon Inc. Revised 2007.
12. Onsolis (fentanyl buccal soluble film). Prescribing information. Meda Pharmaceuticals Inc. 2009.
13. Darwish M, Kirby M, Robertson P, Tracewell W, Jiang JG. Absorption of fentanyl from fentanyl buccal tablet in cancer patients with or without oral mucositis: a pilot study. Clin Drug Investig. 2007;27(9): 605-611.
14. Durfee S, Messina J, Khankari R. Fentanyl effervescent buccal tablets: enhanced buccal absorption. Am J Drug Deliv. 2006;4(1):1-5.
15. Rauck R, North J, Gever LN, Tagarro I, Finn AL. Fentanyl buccal soluble film (FBSF) for breakthrough pain in patients with cancer: a randomized, double-blind, placebo-controlled study. Ann Oncol. 2010; 21(6):1308-1314.
16. Vasisht N, Gever LN, Tagarro I, Finn AL. Single-dose pharmacokinetics of fentanyl buccal soluble film. Pain Med. 2010;11(7):1017-1023.
17. Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events (CTCAE), Version 3.0. August 9, 2006. Available at: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ docs/ctcaev3.pdf. Accessed August 5, 2011.
18. Vasisht N, Gever LN, Tagarro I, Finn AL. Formulation selection and pharmacokinetic comparison of fentanyl buccal soluble film with oral transmucosal fentanyl citrate: a randomized, open-label, single-dose, crossover study. Clin Drug Investig. 2009;29(10):647-654.
19. Dunne M, Rodriguez ES. Mucositis management. Oncology (Williston Park). 2008;22(2 Suppl Nurse Ed):20-23.
20. Naidu MU, Ramana GV, Rani PU, Mohan IK, Suman A, Roy P. Chemotherapy-induced and/or radiation therapy-induced oral mucositis-complicating the treatment of cancer. Neoplasia. 2004;6(5):423-431.
21. Ohrn KE, Wahlin YB, Sjoden PO. Oral status during radiotherapy and chemotherapy: a descriptive study of patient experiences and the occurrence of oral complications. Support Care Cancer. 2001;9(4): 247-257.
22. Shaiova L, Lapin J, Manco LS, et al. Tolerability and effects of two formulations of oral transmucosal fentanyl citrate (OTFC; ACTIQ) in patients with radiation-induced oral mucositis. Support Care Cancer. 2004;12(4):268-273.
23. Zhang H, Zhang J, Streisand JB. Oral mucosal drug delivery: clinical pharmacokinetics and therapeutic applications. Clin Pharmacokinet. 2002;41(9):661-680.
24. Shargel L, Yu ABC. Applied Biopharmaceutics and Pharmacokinetics. 3rd ed. Norwalk, CT: Appleton and Lange; 1993.
25. Pather SI, Rathbone MJ, Senel S. Current status and the future of buccal drug delivery systems. Expert Opin Drug Deliv. 2008;5(5):531-542.
26. Maslennikova AV, Balalaeva IV, Gladkova ND, et al. Use of optical coherence tomography for prognosis of the severity of oral mucositis. Vopr Onkol. 2009;55(5):572-579.
27. Logan RM, Gibson RJ, Bowen JM, Stringer AM, Sonis ST, Keefe DM. Characterisation of mucosal changes in the alimentary tract following administration of irinotecan: implications for the pathobiology of mucositis. Cancer Chemother Pharmacol. 2008;62(1):33-41.
28. Logan RM, Stringer AM, Bowen JM, Gibson RJ, Sonis ST, Keefe DM. Is the pathobiology of chemotherapy-induced alimentary tract mucositis influenced by the type of mucotoxic drug administered? Cancer Chemother Pharmacol. 2009;63(2):239-251.